Janusz W. Koscielniak, Ph.D.

Janusz W. Koscielniak, Ph.D.
Research Engineer III, Leidos Biomedical Research, Inc.
Head, Nuclear Magnetic Resonance Spectroscopy Facility

Dr. Janusz Koscielniak manages the operations of the Nuclear Magnetic Resonance Spectroscopy Facility with access limited to members of three research groups in the Structural Biology Laboratory.

Areas of Expertise
1) NMR spectrometer hardware and software, 2) RF and microwave electronics, 3) low noise signal detection, 4) digital signal processing, 5) high vacuum and cryogenic technology, 6) computer systems administration

Contact Info

Janusz W. Koscielniak, Ph.D.
Center for Cancer Research
National Cancer Institute
Building 538, Room 173
Frederick, MD 21702-1201
Ph: 301-846-1218
Fax: 301-846-6231
koscieja@mail.nih.gov

The Nuclear Magnetic Resonance Spectroscopy Facility provides instrumentation and required support to researchers conducting research on protein and RNA structure determination, protein-protein interactions and dynamics. The facility operates six high-field NMR spectrometers configured for bio-NMR research:  state-of-the-art Bruker Avance III spectrometers equipped with cryoprobes at  850Mhz, 800MHz, 700MHz, and two 600MHz and Varian INOVA 500MHz currently equipped with a room temperature probe dedicated exclusively to 31P experiments. Facility staff provide technical and software support to two other open access NMR facilities located within the Chemical Biology Laboratory and the Molecular Targets Laboratory, which both operate high-throughput NMR spectrometers configured for small molecule type experiments.

Scientific Focus Areas:
Structural Biology

Dr. Janusz Koscielniak received his Ph.D.  in 1983 from Wroclaw University of Technology, Department of Electronics, (Poland) for pioneering work on ultra fast  imaging  methods using Electron Paramagnetic Resonance. After spending five years as a Visiting Fellow at the Department of Chemistry at Ohio State University, he joined the SAIC contract (now Leidos Biomedical Research, Inc.) supporting the NCI CCR research effort in 1995.